These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Author: Tascini C, Flammini S, Leonildi A, Ciullo I, Tagliaferri E, Menichetti F.
    Journal: J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680.
    Abstract:
    Ninety-one clinical isolates of Staphylococcus aureus have been tested with the Kirby Bauer and the Etest® method to determine the susceptibility to glycopeptides in the 2007-2010 period. Five strains (5.5%) were resistant to vancomycin and nine (9.9%) to teicoplanin. Teicoplanin showed a median minimal inhibitory concentration (MIC) of 1 mg/l (range 0.125-24 mg/l), an MIC50 of 1 mg/l, and an MIC90 of 2 mg/l; vancomycin had a median MIC of 1.5 mg/l (range 0.38-4 mg/l), an MIC50 of 1.5 mg/l, and an MIC90 of 2 mg/l. More isolates were distributed on higher values of MIC for vancomycin. Inhibition halos induced by vancomycin-impregnated paper diskettes were slightly larger than those by teicoplanin. Glycopeptide resistance among methicillin-resistant Staphylococcus aureus in Italy is an underestimated phenomenon, possibly due to the described underestimation of glycopeptides MICs by the automatic broth microdilution method, when compared to agar MIC assays. A teicoplanin MIC creep, as reported for vancomycin, cannot be assumed.
    [Abstract] [Full Text] [Related] [New Search]